Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 151

1.

Severe hypoalbuminemia at day 90 predicts worse nonrelapse mortality and overall survival after allogeneic hematopoietic stem cell transplantation for acute myelogenous leukemia and myelodysplastic syndrome.

Kharfan-Dabaja MA, Chavez JC, Yu D, Zhu W, Fernandez-Vertiz EI, Perkins J, Shapiro J, Bookout R, Perez L, Fernandez HF, Komrokji RS, Lancet J, Brand L, Field T, Ayala E, Janssen W, List AF, Anasetti C.

Biol Blood Marrow Transplant. 2011 Mar;17(3):384-93. doi: 10.1016/j.bbmt.2010.07.011. Epub 2010 Jul 22.

PMID:
20655389
[PubMed - indexed for MEDLINE]
2.

Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.

Valcárcel D, Martino R, Caballero D, Martin J, Ferra C, Nieto JB, Sampol A, Bernal MT, Piñana JL, Vazquez L, Ribera JM, Besalduch J, Moraleda JM, Carrera D, Brunet MS, Perez-Simón JA, Sierra J.

J Clin Oncol. 2008 Feb 1;26(4):577-84. Epub 2007 Dec 17.

PMID:
18086801
[PubMed - indexed for MEDLINE]
Free Article
3.

Risk factors for therapy-related myelodysplastic syndrome and acute myeloid leukemia treated with allogeneic stem cell transplantation.

Kröger N, Brand R, van Biezen A, Zander A, Dierlamm J, Niederwieser D, Devergie A, Ruutu T, Cornish J, Ljungman P, Gratwohl A, Cordonnier C, Beelen D, Deconinck E, Symeonidis A, de Witte T; Myelodysplastic Syndromes Subcommittee of The Chronic Leukaemia Working Party of European Group for Blood and Marrow Transplantation (EBMT).

Haematologica. 2009 Apr;94(4):542-9. doi: 10.3324/haematol.2008.000927. Epub 2009 Mar 10.

PMID:
19278968
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome.

McClune BL, Weisdorf DJ, Pedersen TL, Tunes da Silva G, Tallman MS, Sierra J, Dipersio J, Keating A, Gale RP, George B, Gupta V, Hahn T, Isola L, Jagasia M, Lazarus H, Marks D, Maziarz R, Waller EK, Bredeson C, Giralt S.

J Clin Oncol. 2010 Apr 10;28(11):1878-87. doi: 10.1200/JCO.2009.25.4821. Epub 2010 Mar 8.

PMID:
20212255
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Allogeneic hematopoietic cell transplantation for myelodysplastic syndrome: prognostic significance of pre-transplant IPSS score and comorbidity.

Lee JH, Lee JH, Lim SN, Kim DY, Kim SH, Lee YS, Kang YA, Kang SI, Jeon MJ, Seol M, Seo EJ, Chi HS, Park CJ, Jang S, Yun SC, Lee KH.

Bone Marrow Transplant. 2010 Mar;45(3):450-7. doi: 10.1038/bmt.2009.190. Epub 2009 Aug 10.

PMID:
19668236
[PubMed - indexed for MEDLINE]
6.

Marrow fibrosis as a risk factor for posttransplantation outcome in patients with advanced myelodysplastic syndrome or acute myeloid leukemia with multilineage dysplasia.

Scott BL, Storer BE, Greene JE, Hackman RC, Appelbaum FR, Deeg HJ.

Biol Blood Marrow Transplant. 2007 Mar;13(3):345-54.

PMID:
17317588
[PubMed - indexed for MEDLINE]
7.

Validation of the Hematopoietic Cell Transplantation-Specific Comorbidity Index: a prospective, multicenter GITMO study.

Raimondi R, Tosetto A, Oneto R, Cavazzina R, Rodeghiero F, Bacigalupo A, Fanin R, Rambaldi A, Bosi A.

Blood. 2012 Aug 9;120(6):1327-33. doi: 10.1182/blood-2012-03-414573. Epub 2012 Jun 27.

PMID:
22740454
[PubMed - indexed for MEDLINE]
Free Article
8.

Improved outcome in relapsed and refractory myeloid malignancies for unrelated vs related donor allogeneic peripheral blood-derived hematopoietic cell transplantation.

Denz U, Bertz H, Ihorst G, Wäsch R, Finke J.

Bone Marrow Transplant. 2010 Aug;45(8):1309-15. doi: 10.1038/bmt.2009.341. Epub 2010 Jan 11.

PMID:
20062094
[PubMed - indexed for MEDLINE]
9.

Impact of pre-transplant serum ferritin on outcomes of patients with myelodysplastic syndromes or secondary acute myeloid leukaemia receiving reduced intensity conditioning allogeneic haematopoietic stem cell transplantation.

Lim ZY, Fiaccadori V, Gandhi S, Hayden J, Kenyon M, Ireland R, Marsh J, Ho AY, Mufti GJ, Pagliuca A.

Leuk Res. 2010 Jun;34(6):723-7. doi: 10.1016/j.leukres.2009.10.028. Epub 2009 Nov 26.

PMID:
19944463
[PubMed - indexed for MEDLINE]
10.

Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.

Warlick ED, Cioc A, Defor T, Dolan M, Weisdorf D.

Biol Blood Marrow Transplant. 2009 Jan;15(1):30-8. doi: 10.1016/j.bbmt.2008.10.012.

PMID:
19135940
[PubMed - indexed for MEDLINE]
11.

[Prognostic implications of hematopoietic cell transplantation-specific comorbidity index on non-relapse mortality and overall survival after allogeneic hematopoietic stem cell transplantation].

Wang CY, Ren HY, Qiu ZX, Wang Y, Cen XN, Wang LH, Wang MJ, Xu WL, Wang WS, Li Y, Dong YJ, Ou JP, Liang ZY, Liu W, Wang Q.

Zhonghua Xue Ye Xue Za Zhi. 2013 Aug;34(8):659-63. doi: 10.3760/cma.j.issn.0253-2727.2013.08.004. Chinese.

PMID:
23978015
[PubMed - indexed for MEDLINE]
Free Article
12.

Impact of disease burden at time of allogeneic stem cell transplantation in adults with acute myeloid leukemia and myelodysplastic syndromes.

Kebriaei P, Kline J, Stock W, Kasza K, Le Beau MM, Larson RA, van Besien K.

Bone Marrow Transplant. 2005 May;35(10):965-70.

PMID:
15806131
[PubMed - indexed for MEDLINE]
13.

Hematopoietic stem cell transplantation for therapy-related myelodysplastic syndrome and acute leukemia: a single-center analysis of 47 patients.

Yokoyama H, Mori S, Kobayashi Y, Kurosawa S, Saito B, Fuji S, Maruyama D, Azuma T, Kim SW, Watanabe T, Tanosaki R, Tobinai K, Takaue Y, Fukuda T.

Int J Hematol. 2010 Sep;92(2):334-41. doi: 10.1007/s12185-010-0640-7. Epub 2010 Aug 4.

PMID:
20680530
[PubMed - indexed for MEDLINE]
14.

Intravenous busulfan and melphalan, tacrolimus, and short-course methotrexate followed by unmodified HLA-matched related or unrelated hematopoietic stem cell transplantation for the treatment of advanced hematologic malignancies.

Small TN, Young JW, Castro-Malaspina H, Prockop S, Wilton A, Heller G, Boulad F, Chiu M, Hsu K, Jakubowski A, Kernan NA, Perales MA, O'Reilly RJ, Papadopoulos EB.

Biol Blood Marrow Transplant. 2007 Feb;13(2):235-44.

PMID:
17241929
[PubMed - indexed for MEDLINE]
15.

Pretransplant predictors and posttransplant sequels of acute kidney injury after allogeneic stem cell transplantation.

Kagoya Y, Kataoka K, Nannya Y, Kurokawa M.

Biol Blood Marrow Transplant. 2011 Mar;17(3):394-400. doi: 10.1016/j.bbmt.2010.07.010. Epub 2010 Jul 22.

PMID:
20655388
[PubMed - indexed for MEDLINE]
16.

Prognostic factors in patients aged 50 years or older undergoing allogeneic hematopoietic stem cell transplantation for hematologic malignancy.

Takasaki H, Tanaka M, Tachibana T, Numata A, Fujimaki K, Sakai R, Fujisawa S, Tomita N, Fujita H, Maruta A, Ishigatsubo Y, Kanamori H.

Int J Hematol. 2012 Mar;95(3):291-8. doi: 10.1007/s12185-012-1009-x.

PMID:
22302471
[PubMed - indexed for MEDLINE]
17.

Ablative allogeneic hematopoietic cell transplantation in adults 60 years of age and older.

Wallen H, Gooley TA, Deeg HJ, Pagel JM, Press OW, Appelbaum FR, Storb R, Gopal AK.

J Clin Oncol. 2005 May 20;23(15):3439-46. Epub 2005 Apr 11.

PMID:
15824415
[PubMed - indexed for MEDLINE]
Free Article
18.

Outcome of 93 patients with relapse or progression following allogeneic hematopoietic cell transplantation.

Kurosawa S, Fukuda T, Tajima K, Saito B, Fuji S, Yokoyama H, Kim SW, Mori S, Tanosaki R, Heike Y, Takaue Y.

Am J Hematol. 2009 Dec;84(12):815-20. doi: 10.1002/ajh.21555.

PMID:
19899134
[PubMed - indexed for MEDLINE]
19.

Successful prevention of acute graft-versus-host disease using low-dose antithymocyte globulin after mismatched, unrelated, hematopoietic stem cell transplantation for acute myelogenous leukemia.

Kim HJ, Min WS, Cho BS, Eom KS, Kim YJ, Min CK, Lee S, Cho SG, Jin JY, Lee JW, Kim CC.

Biol Blood Marrow Transplant. 2009 Jun;15(6):704-17. doi: 10.1016/j.bbmt.2009.02.010. Epub 2009 Apr 9.

PMID:
19450755
[PubMed - indexed for MEDLINE]
20.

Impact of pretransplant comorbidities on alemtuzumab-based reduced-intensity conditioning allogeneic hematopoietic SCT for patients with high-risk myelodysplastic syndrome and AML.

Lim ZY, Ingram W, Brand R, Ho A, Kenyon M, Devereux S, Marsh J, Mufti GJ, Pagliuca A.

Bone Marrow Transplant. 2010 Apr;45(4):633-9. doi: 10.1038/bmt.2009.236. Epub 2009 Sep 21.

PMID:
19767782
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk